162 related articles for article (PubMed ID: 38319329)
1. Thyroid Cancer: A Review.
Boucai L; Zafereo M; Cabanillas ME
JAMA; 2024 Feb; 331(5):425-435. PubMed ID: 38319329
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib: Role in thyroid cancer and other solid tumors.
Cabanillas ME; Habra MA
Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
[TBL] [Abstract][Full Text] [Related]
3. Molecular targets of tyrosine kinase inhibitors in thyroid cancer.
Fallahi P; Ferrari SM; Galdiero MR; Varricchi G; Elia G; Ragusa F; Paparo SR; Benvenga S; Antonelli A
Semin Cancer Biol; 2022 Feb; 79():180-196. PubMed ID: 33249201
[TBL] [Abstract][Full Text] [Related]
4. Successful recovery from a subclavicular ulcer caused by lenvatinib for thyroid cancer: a case report.
Kitamura M; Hayashi T; Suzuki C; Hirano S; Tateya I; Kishimoto Y; Omori K
World J Surg Oncol; 2017 Jan; 15(1):24. PubMed ID: 28088233
[TBL] [Abstract][Full Text] [Related]
5. Thyroid Carcinoma, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
Haddad RI; Bischoff L; Ball D; Bernet V; Blomain E; Busaidy NL; Campbell M; Dickson P; Duh QY; Ehya H; Goldner WS; Guo T; Haymart M; Holt S; Hunt JP; Iagaru A; Kandeel F; Lamonica DM; Mandel S; Markovina S; McIver B; Raeburn CD; Rezaee R; Ridge JA; Roth MY; Scheri RP; Shah JP; Sipos JA; Sippel R; Sturgeon C; Wang TN; Wirth LJ; Wong RJ; Yeh M; Cassara CJ; Darlow S
J Natl Compr Canc Netw; 2022 Aug; 20(8):925-951. PubMed ID: 35948029
[TBL] [Abstract][Full Text] [Related]
6. Management of thyroid cancer: United Kingdom National Multidisciplinary Guidelines.
Mitchell AL; Gandhi A; Scott-Coombes D; Perros P
J Laryngol Otol; 2016 May; 130(S2):S150-S160. PubMed ID: 27841128
[TBL] [Abstract][Full Text] [Related]
7. Overview of the 2022 WHO Classification of Thyroid Neoplasms.
Baloch ZW; Asa SL; Barletta JA; Ghossein RA; Juhlin CC; Jung CK; LiVolsi VA; Papotti MG; Sobrinho-Simões M; Tallini G; Mete O
Endocr Pathol; 2022 Mar; 33(1):27-63. PubMed ID: 35288841
[TBL] [Abstract][Full Text] [Related]
8. Phase 2 study evaluating the combination of sorafenib and temsirolimus in the treatment of radioactive iodine-refractory thyroid cancer.
Sherman EJ; Dunn LA; Ho AL; Baxi SS; Ghossein RA; Fury MG; Haque S; Sima CS; Cullen G; Fagin JA; Pfister DG
Cancer; 2017 Nov; 123(21):4114-4121. PubMed ID: 28662274
[TBL] [Abstract][Full Text] [Related]
9. Patterns of care for patients with primary differentiated carcinoma of the thyroid gland treated in Germany during 1996. U.S. and German Thyroid Cancer Group.
Hölzer S; Reiners C; Mann K; Bamberg M; Rothmund M; Dudeck J; Stewart AK; Hundahl SA
Cancer; 2000 Jul; 89(1):192-201. PubMed ID: 10897018
[TBL] [Abstract][Full Text] [Related]
10. Current Concepts in the Molecular Genetics and Management of Thyroid Cancer: An Update for Radiologists.
Kelil T; Keraliya AR; Howard SA; Krajewski KM; Braschi-Amirfarzan M; Hornick JL; Ramaiya NH; Tirumani SH
Radiographics; 2016; 36(5):1478-93. PubMed ID: 27618325
[TBL] [Abstract][Full Text] [Related]
11. Molecular diagnosis and targeted treatment of advanced follicular cell-derived thyroid cancer in the precision medicine era.
Capdevila J; Awada A; Führer-Sakel D; Leboulleux S; Pauwels P
Cancer Treat Rev; 2022 May; 106():102380. PubMed ID: 35305441
[TBL] [Abstract][Full Text] [Related]
12. High-Grade Non-Anaplastic Thyroid Carcinomas of Follicular Cell Origin: A Review of Poorly Differentiated and High-Grade Differentiated Carcinomas.
Cracolici V; Cipriani NA
Endocr Pathol; 2023 Mar; 34(1):34-47. PubMed ID: 36692728
[TBL] [Abstract][Full Text] [Related]
13. Interstitial lung disease associated with combination therapy of dabrafenib and trametinib in metastatic BRAF
Zeng Q; Deng Y; Zhang L; Wang W
Int J Clin Pharmacol Ther; 2022 May; 60(5):225-231. PubMed ID: 35072623
[TBL] [Abstract][Full Text] [Related]
14. Kinase inhibitors in thyroid cancers.
Sukrithan V; Jain P; Shah MH; Konda B
Endocr Oncol; 2023 Jan; 3(1):e220062. PubMed ID: 37434642
[TBL] [Abstract][Full Text] [Related]
15. Complete Surgical Resection Following Neoadjuvant Dabrafenib Plus Trametinib in
Wang JR; Zafereo ME; Dadu R; Ferrarotto R; Busaidy NL; Lu C; Ahmed S; Gule-Monroe MK; Williams MD; Sturgis EM; Goepfert RP; Gross ND; Lai SY; Gunn GB; Phan J; Rosenthal DI; Fuller CD; Morrison WH; Iyer P; Cabanillas ME
Thyroid; 2019 Aug; 29(8):1036-1043. PubMed ID: 31319771
[No Abstract] [Full Text] [Related]
16. Molecular Alterations and Comprehensive Clinical Management of Oncocytic Thyroid Carcinoma: A Review and Multidisciplinary 2023 Update.
Bischoff LA; Ganly I; Fugazzola L; Buczek E; Faquin WC; Haugen BR; McIver B; McMullen CP; Newbold K; Rocke DJ; Russell MD; Ryder M; Sadow PM; Sherman E; Shindo M; Shonka DC; Singer MC; Stack BC; Wirth LJ; Wong RJ; Randolph GW
JAMA Otolaryngol Head Neck Surg; 2024 Mar; 150(3):265-272. PubMed ID: 38206595
[TBL] [Abstract][Full Text] [Related]
17. Response to Lenvatinib in Children with Papillary Thyroid Carcinoma.
Mahajan P; Dawrant J; Kheradpour A; Quintanilla NM; Lopez ME; Orth RC; Athanassaki I; Venkatramani R
Thyroid; 2018 Nov; 28(11):1450-1454. PubMed ID: 30226445
[TBL] [Abstract][Full Text] [Related]
18. [Response to lenvatinib in a pediatric patient with respiratory failure associated with papillary thyroid carcinoma].
Dujovne N; Lucero MB; Gazek N; Pitoia F; Felipe L; Ayarzabal V; López Marti J; Ciaccio M; Herzovich V
Arch Argent Pediatr; 2021 Feb; 119(1):e70-e74. PubMed ID: 33458996
[TBL] [Abstract][Full Text] [Related]
19. Real-World Experience with Targeted Therapy for the Treatment of Anaplastic Thyroid Carcinoma.
Iyer PC; Dadu R; Ferrarotto R; Busaidy NL; Habra MA; Zafereo M; Gross N; Hess KR; Gule-Monroe M; Williams MD; Cabanillas ME
Thyroid; 2018 Jan; 28(1):79-87. PubMed ID: 29161986
[TBL] [Abstract][Full Text] [Related]
20. Use of multikinase inhibitors/lenvatinib in singular thyroid cancer scenarios.
Zafón C; Castelo B
Cancer Med; 2022 Oct; 11 Suppl 1(Suppl 1):3-4. PubMed ID: 36202604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]